[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Indexing Sources::
Editorial Board::
Executive Members::
Articles Archive::
Instruction to Authors::
Peer-Review::
Contact Us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 17, Issue 3 (10-2015) ::
J Gorgan Univ Med Sci 2015, 17(3): 101-107 Back to browse issues page
Effect of anti - cyclic citrullinated peptide antibody and Rheumatoid factor on clinical diseases activity index in patients with rheumatoid arthritis
Jafarzadeh L1 , Mobedi Z * 2, Soleimani A3 , Al-e-rasool M4 , Kazemi Vardanjani A5
1- Assistant Professor, Department of Obstetrics and Gynecology, Sahrekord University of Medical Sciences, Shahrekord, Iran
2- Assistant Professor, Department of Rheumatology, Sahrekord University of Medical Sciences, Shahrekord, Iran , z_mobedi@yahoo.com
3- Assistant Professor, Department of Internal Medicine, Sahrekord University of Medical Sciences, Shahrekord, Iran
4- Gynecologist, Sahrekord University of Medical Sciences, Shahrekord, Iran
5- Research Expert, Deputy of Research and Technology, Sahrekord University of Medical Sciences, Shahrekord, Iran
Abstract:   (8009 Views)
Background and Objective: Rheumatoid arthritis is a chronic, inflammatory and systemic disease with peripheral, symmetric polyarthritis symptoms. Several genetic, environmental, and immunological factors contribute greatly to the disease pathogenesis. This study was done to evaluate the effect of anti-cyclic citrullinated peptide (anti - CCP) and rheumatoid factor on clinical disease activity index (CDAI) in the patients with rheumatoid arthritis. Methods: This prospective cohort study was done on 64 rheumatoid arthritis patients according to ACR criteria (1978) whom referred to Rheumatology Clinic of Hajar Hospital in Shahrekord, Iran. Patients were clinically examined for primary CDAI and tested for anti - CCP and rheumatoid factor in the prior and six months after the initiation of the study. Results: 81.3% and 74% of the patients had high titers of anti – CCP antibody and positive rheumatoid factor, respectively. A non-significant recudtion was observed in intensity of secondary clinical activity of the disease in compare to primary clinical activity in the patients with high antibody titer. Conclusion: This study indicated the important role of rheumatoid factor and anti- CCP antibody in the on time diagnosis of rheumatoid arthritis.
Keywords: Rheumatoid arthritis, Anti- CCP antibody, Rheumatoid factor, Clinical disease activity index
Full-Text [PDF 221 kb] [English Abstract]   (12923 Downloads)    
Type of Study: Original Articles | Subject: Internal Medicine
Send email to the article author


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Jafarzadeh L, Mobedi Z, Soleimani A, Al-e-rasool M, Kazemi Vardanjani A. Effect of anti - cyclic citrullinated peptide antibody and Rheumatoid factor on clinical diseases activity index in patients with rheumatoid arthritis. J Gorgan Univ Med Sci 2015; 17 (3) :101-107
URL: http://goums.ac.ir/journal/article-1-2508-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 17, Issue 3 (10-2015) Back to browse issues page
مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.05 seconds with 35 queries by YEKTAWEB 4657